AAPL343.99+4.49 (+1.32%) ▲|ABBV284.80-4.28 (-1.48%) ▼|ABT100.51-1.94 (-1.89%) ▼|ACN240.26+1.14 (+0.48%) ▲|ADBE255.06-1.67 (-0.65%) ▼|AMAT408.94+3.96 (+0.98%) ▲|AMD552.72+17.98 (+3.36%) ▲|AMGN438.34-0.60 (-0.14%) ▼|AMT177.64-5.92 (-3.23%) ▼|AMZN262.37-0.26 (-0.10%) ▼|AVGO337.80+3.43 (+1.03%) ▲|AXP323.61+5.27 (+1.66%) ▲|BA192.28+1.81 (+0.95%) ▲|BAC50.78+0.14 (+0.28%) ▲|BKNG158.38-5.54 (-3.38%) ▼|BLK1,149.60+20.92 (+1.85%) ▲|BMY61.12-0.56 (-0.91%) ▼|BNY145.85+1.60 (+1.11%) ▲|BRK-B538.99-0.83 (-0.15%) ▼|C123.85+1.34 (+1.09%) ▲|CAT740.21+14.97 (+2.06%) ▲|CL93.40-1.14 (-1.21%) ▼|CMCSA22.08-0.28 (-1.25%) ▼|COF206.66+5.10 (+2.53%) ▲|COP145.67-0.28 (-0.19%) ▼|COST998.31+3.70 (+0.37%) ▲|CRM241.78-0.65 (-0.27%) ▼|CSCO107.26+0.55 (+0.52%) ▲|CVS93.45-1.30 (-1.37%) ▼|CVX226.78+1.07 (+0.47%) ▲|DE636.54+4.34 (+0.69%) ▲|DHR233.86+9.62 (+4.29%) ▲|DIS111.83+0.16 (+0.14%) ▲|DUK120.67-0.66 (-0.54%) ▼|EMR163.11+2.65 (+1.65%) ▲|FDX298.23-0.53 (-0.18%) ▼|GD344.71+0.27 (+0.08%) ▲|GE295.88-3.99 (-1.33%) ▼|GEV925.92+35.59 (+4.00%) ▲|GILD153.57-2.94 (-1.88%) ▼|GM76.11-0.98 (-1.27%) ▼|GOOG330.95-5.45 (-1.62%) ▼|GOOGL334.76-5.52 (-1.62%) ▼|GS904.72+19.91 (+2.25%) ▲|HD314.14-0.97 (-0.31%) ▼|HON214.73+1.41 (+0.66%) ▲|IBM251.46+9.54 (+3.94%) ▲|INTC92.96+1.27 (+1.39%) ▲|INTU335.61+0.32 (+0.10%) ▲|ISRG428.12-9.88 (-2.26%) ▼|JNJ257.78-1.58 (-0.61%) ▼|JPM335.19-0.07 (-0.02%) ▼|KO92.68-0.81 (-0.87%) ▼|LIN500.57-1.32 (-0.26%) ▼|LLY1,270.75-12.91 (-1.01%) ▼|LMT551.51+2.80 (+0.51%) ▲|LOW196.56-0.72 (-0.37%) ▼|LRCX260.81-2.64 (-1.00%) ▼|MA622.62+2.20 (+0.35%) ▲|MCD246.25-0.27 (-0.11%) ▼|MDLZ62.74-1.25 (-1.95%) ▼|MDT93.03-1.60 (-1.69%) ▼|META697.52+3.27 (+0.47%) ▲|MMM174.74+3.37 (+1.97%) ▲|MO73.83-0.81 (-1.09%) ▼|MRK149.88+1.58 (+1.07%) ▲|MS187.01+6.61 (+3.66%) ▲|MSFT532.95+1.08 (+0.20%) ▲|MU913.67+17.60 (+1.96%) ▲|NEE78.28-0.58 (-0.74%) ▼|NFLX65.04-3.65 (-5.31%) ▼|NKE37.53-0.35 (-0.92%) ▼|NOW153.12+3.58 (+2.39%) ▲|NVDA221.97+5.50 (+2.54%) ▲|ORCL129.13-2.01 (-1.53%) ▼|PEP134.70+0.68 (+0.51%) ▲|PFE29.85-0.26 (-0.86%) ▼|PG156.84-2.48 (-1.56%) ▼|PLTR201.72+9.12 (+4.74%) ▲|PM197.46-2.44 (-1.22%) ▼|QCOM177.96+2.25 (+1.28%) ▲|RTX191.60-1.74 (-0.90%) ▼|SBUX99.08-0.29 (-0.29%) ▼|SCHW91.64+0.75 (+0.83%) ▲|SO90.39-0.32 (-0.35%) ▼|SPG205.55-1.44 (-0.70%) ▼|T21.91-1.51 (-6.45%) ▼|TMO694.02+6.65 (+0.97%) ▲|TMUS153.75-4.00 (-2.54%) ▼|TSLA386.47+12.76 (+3.41%) ▲|TXN284.65+6.87 (+2.47%) ▲|UBER67.62-1.32 (-1.91%) ▼|UNH417.00-2.26 (-0.54%) ▼|UNP287.87+0.26 (+0.09%) ▲|UPS99.57+1.05 (+1.07%) ▲|USB59.05-0.04 (-0.07%) ▼|V407.85+1.28 (+0.31%) ▲|VZ43.56-0.98 (-2.20%) ▼|WFC82.42+0.22 (+0.27%) ▲|WMT117.80-0.05 (-0.04%) ▼|XOM178.09+0.23 (+0.13%) ▲|AAPL343.99+4.49 (+1.32%) ▲|ABBV284.80-4.28 (-1.48%) ▼|ABT100.51-1.94 (-1.89%) ▼|ACN240.26+1.14 (+0.48%) ▲|ADBE255.06-1.67 (-0.65%) ▼|AMAT408.94+3.96 (+0.98%) ▲|AMD552.72+17.98 (+3.36%) ▲|AMGN438.34-0.60 (-0.14%) ▼|AMT177.64-5.92 (-3.23%) ▼|AMZN262.37-0.26 (-0.10%) ▼|AVGO337.80+3.43 (+1.03%) ▲|AXP323.61+5.27 (+1.66%) ▲|BA192.28+1.81 (+0.95%) ▲|BAC50.78+0.14 (+0.28%) ▲|BKNG158.38-5.54 (-3.38%) ▼|BLK1,149.60+20.92 (+1.85%) ▲|BMY61.12-0.56 (-0.91%) ▼|BNY145.85+1.60 (+1.11%) ▲|BRK-B538.99-0.83 (-0.15%) ▼|C123.85+1.34 (+1.09%) ▲|CAT740.21+14.97 (+2.06%) ▲|CL93.40-1.14 (-1.21%) ▼|CMCSA22.08-0.28 (-1.25%) ▼|COF206.66+5.10 (+2.53%) ▲|COP145.67-0.28 (-0.19%) ▼|COST998.31+3.70 (+0.37%) ▲|CRM241.78-0.65 (-0.27%) ▼|CSCO107.26+0.55 (+0.52%) ▲|CVS93.45-1.30 (-1.37%) ▼|CVX226.78+1.07 (+0.47%) ▲|DE636.54+4.34 (+0.69%) ▲|DHR233.86+9.62 (+4.29%) ▲|DIS111.83+0.16 (+0.14%) ▲|DUK120.67-0.66 (-0.54%) ▼|EMR163.11+2.65 (+1.65%) ▲|FDX298.23-0.53 (-0.18%) ▼|GD344.71+0.27 (+0.08%) ▲|GE295.88-3.99 (-1.33%) ▼|GEV925.92+35.59 (+4.00%) ▲|GILD153.57-2.94 (-1.88%) ▼|GM76.11-0.98 (-1.27%) ▼|GOOG330.95-5.45 (-1.62%) ▼|GOOGL334.76-5.52 (-1.62%) ▼|GS904.72+19.91 (+2.25%) ▲|HD314.14-0.97 (-0.31%) ▼|HON214.73+1.41 (+0.66%) ▲|IBM251.46+9.54 (+3.94%) ▲|INTC92.96+1.27 (+1.39%) ▲|INTU335.61+0.32 (+0.10%) ▲|ISRG428.12-9.88 (-2.26%) ▼|JNJ257.78-1.58 (-0.61%) ▼|JPM335.19-0.07 (-0.02%) ▼|KO92.68-0.81 (-0.87%) ▼|LIN500.57-1.32 (-0.26%) ▼|LLY1,270.75-12.91 (-1.01%) ▼|LMT551.51+2.80 (+0.51%) ▲|LOW196.56-0.72 (-0.37%) ▼|LRCX260.81-2.64 (-1.00%) ▼|MA622.62+2.20 (+0.35%) ▲|MCD246.25-0.27 (-0.11%) ▼|MDLZ62.74-1.25 (-1.95%) ▼|MDT93.03-1.60 (-1.69%) ▼|META697.52+3.27 (+0.47%) ▲|MMM174.74+3.37 (+1.97%) ▲|MO73.83-0.81 (-1.09%) ▼|MRK149.88+1.58 (+1.07%) ▲|MS187.01+6.61 (+3.66%) ▲|MSFT532.95+1.08 (+0.20%) ▲|MU913.67+17.60 (+1.96%) ▲|NEE78.28-0.58 (-0.74%) ▼|NFLX65.04-3.65 (-5.31%) ▼|NKE37.53-0.35 (-0.92%) ▼|NOW153.12+3.58 (+2.39%) ▲|NVDA221.97+5.50 (+2.54%) ▲|ORCL129.13-2.01 (-1.53%) ▼|PEP134.70+0.68 (+0.51%) ▲|PFE29.85-0.26 (-0.86%) ▼|PG156.84-2.48 (-1.56%) ▼|PLTR201.72+9.12 (+4.74%) ▲|PM197.46-2.44 (-1.22%) ▼|QCOM177.96+2.25 (+1.28%) ▲|RTX191.60-1.74 (-0.90%) ▼|SBUX99.08-0.29 (-0.29%) ▼|SCHW91.64+0.75 (+0.83%) ▲|SO90.39-0.32 (-0.35%) ▼|SPG205.55-1.44 (-0.70%) ▼|T21.91-1.51 (-6.45%) ▼|TMO694.02+6.65 (+0.97%) ▲|TMUS153.75-4.00 (-2.54%) ▼|TSLA386.47+12.76 (+3.41%) ▲|TXN284.65+6.87 (+2.47%) ▲|UBER67.62-1.32 (-1.91%) ▼|UNH417.00-2.26 (-0.54%) ▼|UNP287.87+0.26 (+0.09%) ▲|UPS99.57+1.05 (+1.07%) ▲|USB59.05-0.04 (-0.07%) ▼|V407.85+1.28 (+0.31%) ▲|VZ43.56-0.98 (-2.20%) ▼|WFC82.42+0.22 (+0.27%) ▲|WMT117.80-0.05 (-0.04%) ▼|XOM178.09+0.23 (+0.13%) ▲|
12.9 C
New York
Thursday, October 22, 2026

Tag: treatment options

newsFORsourcecompanycontentinformation1releasesmarket

4 Emerging Graft versus Host Disease Therapies That Could Change the Treatment Landscape | DelveInsight

Key companies, such as CSL Behring, Equillium, Biocon, and medac, are advancing their assets through late-stage graft versus host disease clinical trials, driving innovation...

Cancer Pain Market Set to Transform by 2034 Due to Launch of Breakthrough Therapies | DelveInsight

According to DelveInsight's analysis, the growth of the cancer pain market is expected to be mainly driven by increasing incidence and advances in disease...

DBV Technologies to Participate in Upcoming EAACI Congress 2025

Châtillon, France, June 12, 2025

Dignify Therapeutics Announces Jeff Welch as Chief Operating Officer

RESEARCH TRIANGLE PARK, N.C., June 12, 2025 /PRNewswire/ -- Dignify Therapeutics (Dignify), a pharmaceutical and medical device development company focused on restoring bowel and bladder...

European Commission Grants Orphan Drug Designation to Florbetaben (18F) for Diagnosis of ATTR Amyloidosis

Florbetaben (18F) has been granted Orphan drug designation for the diagnosis of ATTR amyloidosisFlorbetaben (18F) previously received orphan drug designation as a diagnostic agent...

Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases

Protection through 2039, ensuring long-term commercial exclusivity. NEW YORK, June 12, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing innovative...

Sharecare introduces new interactive solutions to elevate health literacy and increase condition-specific treatment adherence

Utilizing augmented reality, artificial intelligence, and time-based visualization, Sharecare’s newest innovative tools help life sciences brands engage, educate, and activate patients 
Utilizing augmented reality, artificial intelligence, and time-based visualization, Sharecare’s newest innovative tools help life sciences brands engage, educate, and activate patients

RadioMedix Debuts Proprietary bench top ²¹²Pb Generator to Support Targeted Alpha Therapy Development

New bench top ²¹²Pb generator to expand clinical-grade isotope supply for targeted alpha therapy research and development 
New bench top ²¹²Pb generator to expand clinical-grade isotope supply for targeted alpha therapy research and development

Karmanos Cancer Institute Continues Community Education Series in June: Understanding Lung Cancer Diagnosis and Treatment Options

The Community Conversations on Cancer seminar series, in partnership with the Detroit Public Library, allows Michigan residents to learn from researchers and physician-scientists DETROIT, June...

Medical Second Opinion Market to Hit USD 19.03 Billion by 2029, Driven by Cancer and Chronic Care | Valuates Reports

BANGALORE, India, June 12, 2025 /PRNewswire/ -- Medical Second Opinion Market is Segmented by Type (Hospitals, Medical Second Opinion Providing Companies, Health Insurance Companies),...

Enterome raises $19 million to fund clinical development of its OncoMimics™ immunotherapy to treat Follicular Lymphoma

Paris, France – June 12, 2025

Enterome SA, a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer, has raised $19 million in a new private financing to advance its lead clinical program EO2463 OncoMimics™ immunotherapy to treat indolent non-Hodgkin lymphoma (iNHL). The new funds will be used to expand and finalize the ongoing Phase 1/2 SIDNEY clinical trial of EO2463 and prepare the candidate for a registrational trial.

Significant efficacy benefit of IMBRUVICA® (ibrutinib) plus venetoclax versus acalabrutinib plus venetoclax in frontline treatment of patients with chronic lymphocytic leukaemia suggested by indirect...

Cross-study findings indicate significant clinical benefit of frontline fixed-duration ibrutinib plus venetoclax with improved likelihood of undetectable minimal residual disease and progression-free survival versus acalabrutinib plus venetoclax1

DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting

Châtillon, France, June 11, 2025

Home Healthcare Market Share Worth $666.91 billion, Globally, by 2030 – Exclusive Study by The Research Insights

CHICAGO, June 11, 2025 /PRNewswire/ -- The Global Home Healthcare Market share is projected to be valued at USD 420.79 billion in 2024 and reach USD...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTreatment options

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers